Navigation Links
China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income

-- Expects Revenue of $88 to $90 Million and Net Income of $27 to $28


HARBIN, China, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has increased its revenue and earnings guidance for the full-year 2008 period.

China Sky One Medical raised its full-year 2008 revenue guidance to $88- $90 million, up from its prior guidance of $81-$83 million, previously announced on August 12, 2008. In addition, the Company now estimates that full-year 2008 net income will be in the range of $27-$28 million, up from its previous estimate of $25.9-$26.6 million. China Sky One Medical expects 2008 gross margin to be approximately 77%. The Company's previous estimate for 2008 gross margin was 78.5%.

The increase in the Company's 2008 financial estimates is primarily due to strong results from an advertising campaign for its products that was launched in the second quarter, as well as expected contributions from acquisitions made in 2008. The Company recently started production at Peng Lai Jin Chuang Company ("Jin Chuang"), a newly established pharmaceutical company acquired in June. While Jin Chuang is expected to have a positive impact on 2008 results, it will take time for the Company to ramp up its manufacturing capacity and optimize efficiency in order to achieve large scale production. The Company is also increasing its level of R&D spending in the second half of 2008 to support its growing new product pipeline.

"Our business continues to perform well, and our recent acquisitions and the success of a large advertising campaign for our products that we launched in the second quarter are helping to drive our sales," said Mr. Yan-Qing Liu, Chairman, President, and CEO of China Sky One Medicine Inc. "We believe that we will see strong future growth as we continue our strategy of hiring direct territory managers and sales agents to strengthen our distribution channels, as well as increase our R&D to develop a wider range of new and exciting products."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the- counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069


Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915


Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516



SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
2. Chinas Farmers Welcome the New Trend of Organic Farming
3. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
6. China Biopharma Effects 1 for 100 Reverse Stock Split
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. China Yingxia International, Inc. Appoints New Vice President of Finance
9. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
10. China Biologic Products to Present at the SIG Beijing Management Summit
11. China Biologics Production Facility Renews GMP Certification
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):